Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Unraveling Clonal Evolution and Mechanisms of Treatment Resistance in Murine KMT2A -Rearranged Leukemia with Subclonal FLT3 N676K

Ton Falques-Costa, Mattias Pilheden, Andrea Hanel, Qirui Zhang, Louise Ahlgren, Helena Sturesson, Lars Ronnstrand, Julhash Uddin Kazi, Merja Heinäniemi, Axel Hyrenius Wittsten, Anna K. Hagstroem-Andersson

Blood (2023) 142 (Supplement 1): 5918.

https://doi.org/10.1182/blood-2023-180636

Published: 2023

Journal Articles

Treatment Shapes Clonal Evolution and Resistance Patterns in Murine KMT2A -Rearranged Leukemia with Subclonal FLT3 N676K

Ton Falqués, Mattias Pilheden, Qirui Zhang, Louise Ahlgren, Helena Sturesson, Lars Ronnstrand, Axel Hyrenius Wittsten, Julhash U. Kazi, Anna Hagstroem-Andersson

Blood (2021) 138 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2021-144760

Published: 2021

Journal Articles

FLT3 Is Sumoylated and Localizes to the Nucleus in Acute Myeloid Leukemia

Marisse Asong, MD MSc, Julhash Uddin Kazi, PhD, Lars Ronnstrand, PhD

Blood (2019) 134 (Supplement_1): 2733.

https://doi.org/10.1182/blood-2019-127914

Published: 2019

Journal Articles

Internal Tandem Duplication (ITD) in the Tyrosine Kinase Domain of FLT3 Displays Higher Oncogenic Potential in Acute Myeloid Leukemia

Alissa Marhäll, PhD student, Thomas Fischer, MD, Florian H. Heidel, MD, Julhash U. Kazi, PhD, Lars Rönnstrand, PhD

Blood (2016) 128 (22): 5118.

https://doi.org/10.1182/blood.V128.22.5118.5118

Published: 2016

Journal Articles

Tyrosine 842 Residue in the Activation Loop of FLT3-ITD Is Indespensible for Oncogenic Transformation

Julhash U. Kazi, PhD, Lars Rönnstrand, PhD

Blood (2016) 128 (22): 1561.

https://doi.org/10.1182/blood.V128.22.1561.1561

Published: 2016

Journal Articles

Loss of Src-like Adaptor Protein 2 Expression Increases the Transforming Potential of Oncogenic FLT3-ITD

Sausan A. Moharram, MS, Julhash U. Kazi, PhD, Lars Rönnstrand, PhD

Blood (2016) 128 (22): 5106.

https://doi.org/10.1182/blood.V128.22.5106.5106

Published: 2016

Journal Articles

Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to Sorafenib in AML

Oscar Lindblad, Eugenio Cordero, Alexandre Puissant, Lucy Macaulay, Nuzhat N. Kabir, Jianmin Sun, Karin Haraldsson, Åke Borg, Fredrik Levander, Kimberly Stegmaier, MD, Kristian Pietras, Lars Ronnstrand, Julhash U. Kazi

Blood (2015) 126 (23): 2472.

https://doi.org/10.1182/blood.V126.23.2472.2472

Published: 2015

Journal Articles

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3

De-Chen Lin, Tong Yin, Maya Koren-Michowitz, Ling-Wen Ding, Saskia Gueller, Sigal Gery, Takayuki Tabayashi, Ulla Bergholz, Julhash U. Kazi, Lars Rönnstrand, Carol Stocking, H. Phillip Koeffler

Blood (2012) 120 (16): 3310–3317.

https://doi.org/10.1182/blood-2011-10-388611

Published: 2012

Includes: Supplemental data

Journal Articles

SRC is a signaling mediator in FLT3-ITD– but not in FLT3-TKD–positive AML

Hannes Leischner, Corinna Albers, Rebekka Grundler, Elena Razumovskaya, Karsten Spiekermann, Stefan Bohlander, Lars Rönnstrand, Katharina Götze, Christian Peschel, Justus Duyster

Blood (2012) 119 (17): 4026–4033.

https://doi.org/10.1182/blood-2011-07-365726

Published: 2012

Includes: Supplemental data

Journal Articles

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD –induced myeloproliferation

Shabnam Kharazi, Adam J. Mead, Anna Mansour, Anne Hultquist, Charlotta Böiers, Sidinh Luc, Natalija Buza-Vidas, Zhi Ma, Helen Ferry, Debbie Atkinson, Kristian Reckzeh, Kristina Masson, Jörg Cammenga, Lars Rönnstrand, Fumio Arai, Toshio Suda, Claus Nerlov, Ewa Sitnicka, Sten Eirik W. Jacobsen

Blood (2011) 118 (13): 3613–3621.

https://doi.org/10.1182/blood-2010-06-289207

Published: 2011

Includes: Supplemental data

Journal Articles

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

Frank Breitenbuecher, Boyka Markova, Stefan Kasper, Birgit Carius, Torsten Stauder, Frank D. Böhmer, Kristina Masson, Lars Rönnstrand, Christoph Huber, Thomas Kindler, Thomas Fischer

Blood (2009) 113 (17): 4063–4073.

https://doi.org/10.1182/blood-2007-11-126664

Published: 2009

Includes: Supplemental data

Journal Articles

Identification of Novel Phosphorylation Sites and Kinetics in Flt3 Receptor Wt, ITD and D835Y

Elena Razumovskaya, Kristina Masson, Rasheed Khan, Susanne Bengtsson, Lars Ronnstrand

Blood (2008) 112 (11): 5395.

https://doi.org/10.1182/blood.V112.11.5395.5395

Published: 2008

Journal Articles

Identification of Tyrosine Residues of Importance for Survival Signaling through the Scaffolding Protein Gab2 in Both Wild-Type FLT3 and the FLT3-ITD.

Kristina Masson, MSc, Tao Liu, PhD, Jianmin Sun, PhD, Lars Ronnstrand, PhD

Blood (2007) 110 (11): 1622.

https://doi.org/10.1182/blood.V110.11.1622.1622

Published: 2007

Journal Articles

Negative Regulation of c-Kit Is Dependent on Direct Binding of Cbl to Tyrosines 568 and 936.

Kristina Masson, MSc, Elke Heiss, Ph.D, Lars Ronnstrand, Ph.D

Blood (2005) 106 (11): 2288.

https://doi.org/10.1182/blood.V106.11.2288.2288

Published: 2005

Journal Articles

Identification of Two Src Recruitment Sites in the Juxtamembrane Region of Flt3 with Opposing Effects on Flt3-Ligand-Induced Signaling.

Lars Ronnstrand, PhD, Elke Heiss, PhD, Christina Sundberg, PhD, Kristina Masson, MSc, Malin Pedersen, MSc, Jianmin Sun, PhD, Susanne Bengtsson

Blood (2005) 106 (11): 2289.

https://doi.org/10.1182/blood.V106.11.2289.2289

Published: 2005

Journal Articles

Splice Form Specific Signaling of the Hematopoietic Growth Factor Receptor c-Kit.

Malin Pedersen, MSc, Christina Sundberg, Ph.D, Lars Ronnstrand, Ph.D

Blood (2005) 106 (11): 4284.

https://doi.org/10.1182/blood.V106.11.4284.4284

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Unraveling Clonal Evolution and Mechanisms of Treatment Resistance in Murine KMT2A -Rearranged Leukemia with Subclonal FLT3 N676K

Treatment Shapes Clonal Evolution and Resistance Patterns in Murine KMT2A -Rearranged Leukemia with Subclonal FLT3 N676K

FLT3 Is Sumoylated and Localizes to the Nucleus in Acute Myeloid Leukemia

Internal Tandem Duplication (ITD) in the Tyrosine Kinase Domain of FLT3 Displays Higher Oncogenic Potential in Acute Myeloid Leukemia

Tyrosine 842 Residue in the Activation Loop of FLT3-ITD Is Indespensible for Oncogenic Transformation

Loss of Src-like Adaptor Protein 2 Expression Increases the Transforming Potential of Oncogenic FLT3-ITD

Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to Sorafenib in AML

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3

SRC is a signaling mediator in FLT3-ITD– but not in FLT3-TKD–positive AML

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD –induced myeloproliferation

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

Identification of Novel Phosphorylation Sites and Kinetics in Flt3 Receptor Wt, ITD and D835Y

Identification of Tyrosine Residues of Importance for Survival Signaling through the Scaffolding Protein Gab2 in Both Wild-Type FLT3 and the FLT3-ITD.

Negative Regulation of c-Kit Is Dependent on Direct Binding of Cbl to Tyrosines 568 and 936.

Identification of Two Src Recruitment Sites in the Juxtamembrane Region of Flt3 with Opposing Effects on Flt3-Ligand-Induced Signaling.

Splice Form Specific Signaling of the Hematopoietic Growth Factor Receptor c-Kit.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only